Vor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of "Buy" from Analysts

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $11.36.

Several research firms recently commented on VOR. HC Wainwright reiterated a "buy" rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Friday, November 8th. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Vor Biopharma in a research note on Friday, November 8th. Robert W. Baird lowered their target price on Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating for the company in a report on Friday, November 8th. JMP Securities reaffirmed a "market outperform" rating and set a $12.00 target price on shares of Vor Biopharma in a report on Friday, September 6th. Finally, Barclays decreased their price objective on Vor Biopharma from $10.00 to $3.00 and set an "overweight" rating for the company in a report on Wednesday, August 14th.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new stake in shares of Vor Biopharma in the first quarter valued at about $126,000. Vanguard Group Inc. lifted its stake in Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company's stock worth $4,297,000 after purchasing an additional 69,436 shares during the period. Hsbc Holdings PLC raised its stake in shares of Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company's stock valued at $51,000 after acquiring an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Vor Biopharma in the second quarter valued at approximately $53,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vor Biopharma in the second quarter valued at approximately $63,000. Institutional investors own 97.29% of the company's stock.

Vor Biopharma Stock Performance

Shares of NYSE VOR traded down $0.01 during trading on Friday, reaching $0.78. The company had a trading volume of 338,895 shares, compared to its average volume of 503,017. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14. The stock has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $1.02.

Vor Biopharma (NYSE:VOR - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, meeting analysts' consensus estimates of ($0.40). As a group, analysts predict that Vor Biopharma will post -1.55 earnings per share for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.